Researchers with Diakonos Oncology are working to extend the lives of other patients diagnosed with other forms of cancer.

The patient was dosed at Austin Health in Melbourne, Australia, under the supervision of Professor Hui Gan. IPAX BrIGHT is assessing the safety and efficacy of TLX101-Tx in combination with ...

Alpheus Medical, Inc., a private, clinical-stage biotechnology company, today announced the initiation of its Phase 2b randomized controlled trial in newly diagnosed glioblastoma (nGBM) with 10 ...

Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the ...

Researchers headed by teams at Mass General Brigham Cancer Institute and Harvard Medical School have acquired serial biopsies from two recurrent glioblastoma (rGBM) patients who were involved in an ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, today announced updated Phase 2 ...

When Fran Noonan was told she would have the opportunity to enroll in a new clinical trial for glioblastoma multiforme (GBM), she could not get to Cleveland fast enough. She put her full trust in ...

In a healthcare environment where 77% of cancer genomic testing claims were denied by private insurers in 2024, the Foundation has made a bold and unprecedented commitment: every glioblastoma patient ...

Glioblastoma patients, long shut out from immunotherapies that have transformed patient care in other cancers, could finally benefit from a new treatment option. Boston cancer researchers have found ...

DURHAM, NC / ACCESS Newswire / July 16, 2025 / On Glioblastoma Awareness Day, the Glioblastoma Foundation proudly announces the official launch of Gliolab, a CLIA-certified genomic testing laboratory ...